Australia is eagerly awaiting the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://elodiefnxc522655.wikistatement.com/5896983/this_new_drug_retatrutide_australia_a_potential_breakthrough_for_obesity_treatment